Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices
Year: 2025
Type: article
Study design: Observational Study
Source: Expert Review of Hematology
Institutions: Flatiron Health (United States), Pfizer (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W4409551618
